P J Goadsby

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Migraine in pregnancy
    Peter J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, CA 94143-0114, USA
    BMJ 336:1502-4. 2008
  2. ncbi The trigeminocervical complex and migraine: current concepts and synthesis
    T Bartsch
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Curr Pain Headache Rep 7:371-6. 2003
  3. ncbi Pituitary volume and headache: size is not everything
    Miles J Levy
    Headache Group and the Department of Radiology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, England
    Arch Neurol 61:721-5. 2004
  4. ncbi Migraine: emerging treatment options for preventive and acute attack therapy
    Peter J Goadsby
    Institute of Neurology, Headache Group, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Expert Opin Emerg Drugs 11:419-27. 2006
  5. ncbi On the functional neuroanatomy of neck pain
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, CA, USA
    Cephalalgia 28:1-7. 2008
  6. ncbi Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine
    Michele Viana
    Headache Group Department of Neurology, University of California, San Francisco, CA 94115, USA
    J Neurol Neurosurg Psychiatry 83:663-5. 2012
  7. ncbi Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments
    Peter J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, San Francisco California 94143 0114, USA
    Curr Opin Neurol 21:323-30. 2008
  8. ncbi The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
    Cephalalgia 28:36-41. 2008
  9. ncbi Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis
    P J Goadsby
    Headache Group, Institute of Neurology, London, UK
    Cephalalgia 29:742-50. 2009
  10. ncbi Neurobiology of migraine
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    Neuroscience 161:327-41. 2009

Collaborators

Detail Information

Publications120 found, 100 shown here

  1. ncbi Migraine in pregnancy
    Peter J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, CA 94143-0114, USA
    BMJ 336:1502-4. 2008
  2. ncbi The trigeminocervical complex and migraine: current concepts and synthesis
    T Bartsch
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Curr Pain Headache Rep 7:371-6. 2003
    ..The pathophysiology and functional relevance of these basic mechanisms to headaches is discussed in the context of recent experimental findings with regard to pain processing...
  3. ncbi Pituitary volume and headache: size is not everything
    Miles J Levy
    Headache Group and the Department of Radiology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, England
    Arch Neurol 61:721-5. 2004
    ..Elucidating these mechanisms will aid in the treatment of these patients and further our understanding of other headache syndromes...
  4. ncbi Migraine: emerging treatment options for preventive and acute attack therapy
    Peter J Goadsby
    Institute of Neurology, Headache Group, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Expert Opin Emerg Drugs 11:419-27. 2006
    ..Device-based approaches using neurostimulation of the occipital nerve are being studied, although the first study of patent foramen ovale closure for migraine prevention failed...
  5. ncbi On the functional neuroanatomy of neck pain
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, CA, USA
    Cephalalgia 28:1-7. 2008
  6. ncbi Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine
    Michele Viana
    Headache Group Department of Neurology, University of California, San Francisco, CA 94115, USA
    J Neurol Neurosurg Psychiatry 83:663-5. 2012
    ..Harlequin syndrome (HS) is a rare autonomic disorder characterised by unilateral diminished sweating and flushing of the face in response to heat or exercise. Some patients with HS complain of headache...
  7. ncbi Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments
    Peter J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, San Francisco California 94143 0114, USA
    Curr Opin Neurol 21:323-30. 2008
    ..Hemicrania continua is included for completeness...
  8. ncbi The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
    Cephalalgia 28:36-41. 2008
    ..Treatment with almotriptan while migraine pain is still mild and within 1 h of onset provides statistically significant and clinically relevant enhancements in efficacy compared with waiting until pain has reached higher severity levels...
  9. ncbi Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis
    P J Goadsby
    Headache Group, Institute of Neurology, London, UK
    Cephalalgia 29:742-50. 2009
    ..The good tolerability and promising efficacy results support further exploration of higher doses of tonabersat in larger controlled trials...
  10. ncbi Neurobiology of migraine
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    Neuroscience 161:327-41. 2009
    ..Migraine may thus be considered an inherited dysfunction of sensory modulatory networks with the dominant disturbance affecting abnormal processing of essentially normal neural traffic...
  11. ncbi Trigeminal autonomic cephalalgias: paroxysmal hemicrania, SUNCT/SUNA, and hemicrania continua
    Peter J Goadsby
    Headache Group, Department of Neurology, University of California San Francisco, San Francisco, California, USA
    Semin Neurol 30:186-91. 2010
    ..The syndromes share much in their pathophysiology and investigation paths; however, their treatment is distinct, so that the accurate differentiation is important for optimal management...
  12. ncbi [Pathophysiology and treatment of trigeminal autonomic cephalalgias]
    P J Goadsby
    Headache Group, Department of Neurology, University of California, San Francisco, CA, USA
    Schmerz 22:7-10. 2008
    ..It is important to recognize and differentiate between these syndromes because they react very well, but very selectively to therapy...
  13. ncbi Inhibition of nociceptive dural input in the trigeminal nucleus caudalis by somatostatin receptor blockade in the posterior hypothalamus
    T Bartsch
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Pain 117:30-9. 2005
    ....
  14. ncbi Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat
    P R Holland
    Headache Group, Institute of Neurology, Queen Square, London, UK
    Eur J Neurosci 24:2825-33. 2006
    ..The current study demonstrates that orexin A is able to inhibit A-fibre responses to dural electrical stimulation via activation of the OX(1)R...
  15. ncbi Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area
    T Bartsch
    Headache Group, Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Pain 109:367-78. 2004
    ....
  16. ncbi Evidence for postjunctional serotonin (5-HT1) receptors in the trigeminocervical complex
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Ann Neurol 50:804-7. 2001
    ..These data establish the existence of triptan-sensitive (5-HT1) receptors on postsynaptic central trigeminal neurones...
  17. ncbi Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Neurology 54:156-63. 2000
    ..To compare the efficacy, safety, and tolerability of oral eletriptan (20 mg, 40 mg, and 80 mg) with that of oral sumatriptan (100 mg) and placebo for the acute treatment of migraine...
  18. ncbi Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Pain 82:15-22. 1999
    ..The data suggest that activation of the 5HT(1B/1D) receptor is important for the clinical action of this class of compounds and is consistent with the fact the CP122,288 is ineffective in the treatment of the acute attack of migraine...
  19. ncbi The periaqueductal grey matter modulates trigeminovascular input: a role in migraine?
    Y E Knight
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, UK
    Neuroscience 106:793-800. 2001
    ..Considered with neurosurgical and human functional imaging studies, these data support the notion that brainstem dysfunction might lead to disinhibition of trigeminal afferents and be important in the pain process of migraines...
  20. ncbi Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat
    K G Shields
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Neuroscience 135:203-12. 2005
    ..We discuss the evidence to suggest a role for VDCCs in the pathophysiology of primary headache disorders, and how abnormalities of function may contribute to their pathogenesis...
  21. ncbi GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex
    R J Storer
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London
    Br J Pharmacol 134:896-904. 2001
    ..GABA(A) receptors may therefore provide a target for the development of new therapeutic agents for primary headache disorders...
  22. ncbi Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception
    P R Holland
    Headache Group, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    J Pharmacol Exp Ther 315:1380-5. 2005
    ..The current study demonstrates that orexin A is able to inhibit neurogenic dural vasodilation via activation of the OX1 receptor, resulting in inhibition of prejunctional release of CGRP from trigeminal neurons...
  23. ncbi The clinical characteristics of headache in patients with pituitary tumours
    M J Levy
    Headache Group, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Brain 128:1921-30. 2005
    ..A proposed modification of the current classification of pituitary-associated headache is given...
  24. ncbi Greater occipital nerve injection in primary headache syndromes--prolonged effects from a single injection
    S K Afridi
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Pain 122:126-9. 2006
    ..It is remarkable that in all conditions in which an effect is observed the response time so much exceeds the local anesthetic effect that the mechanism of action may well be through changes in brain nociceptive pathways...
  25. ncbi Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception
    S Akerman
    Headache Group, Institute of Neurology and National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    J Pharmacol Exp Ther 309:56-63. 2004
    ..It can be suggested that anandamide is tonically released to play some form of modulatory role in the trigeminovascular system...
  26. ncbi Nociceptive-specific blink reflex and glyceryl trinitrate infusion in healthy volunteers
    F Kowacs
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Eur J Neurol 10:295-9. 2003
    ..Although mild headache was induced in six subjects, there was no significant change between the R2 area under the curve before and after drug vs. placebo...
  27. ncbi How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians
    R B Lipton
    Department of Neurology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Curr Med Res Opin 21:413-24. 2005
    ..In treating migraine sufferers, physicians can choose from among seven triptans with different attributes...
  28. ncbi Properties of neurons in the trigeminal nucleus caudalis responding to noxious dural and facial stimulation
    S Bolton
    Headache Group, Institute of Neurology, London, UK
    Brain Res 1046:122-9. 2005
    ....
  29. ncbi Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation
    S Akerman
    Headache Group, Institute of Neurology, Queen Square, London WCIN 3BG
    Br J Pharmacol 140:718-24. 2003
    ..The data imply that the VR1 receptor plays only a minor role in trigeminovascular-induced dural vessel dilation...
  30. ncbi Occipital afferent activation of second order neurons in the trigeminocervical complex in rat
    K Le Doaré
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Neurosci Lett 403:73-7. 2006
    ....
  31. ncbi The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat
    J D Classey
    Headache Group, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, UK
    Brain Res 907:117-24. 2001
    ..Understanding glutamatergic mechanisms in the trigeminocervical complex offers mechanistic insight and therapeutic possibilities for primary neurovascular headaches, such as migraine...
  32. ncbi 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity?
    Y E Knight
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Neuropharmacology 40:520-5. 2001
    ..Taken with the clinical results, these data emphasise the importance of CGRP release in migraine, and suggest that other non-5HT-based pharmacological targets may account for PPE blockade in animal studies...
  33. ncbi Stimulation of the greater occipital nerve increases metabolic activity in the trigeminal nucleus caudalis and cervical dorsal horn of the cat
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Pain 73:23-8. 1997
    ....
  34. ncbi 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses
    R J Storer
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, WC1N 3BG, London, UK
    Neuropharmacology 40:911-7. 2001
    ..To account for neurogenic dural plasma protein extravasation blockade in animal studies, 4991W93 might have non-5-HT(1B/1D)-based pharmacological targets that are yet to be described...
  35. ncbi Treatment-emergent CNS symptoms following triptan therapy are part of the attack
    P J Goadsby
    Institute of Neurology, London, UK
    Cephalalgia 27:254-62. 2007
    ..The rate of somnolence in placebo responders is comparable to that in responders to E40 and E80, indicating that somnolence is related, at least in some important part, to headache relief and not treatment...
  36. ncbi Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission
    R J Storer
    Department of Neurology, University of California, San Francisco, California 94143 0114, USA
    Cephalalgia 29:1242-58. 2009
    ....
  37. ncbi The effect of adrenergic compounds on neurogenic dural vasodilatation
    S Akerman
    Headache Group, Institute of Neurology, Queen Square, WC1N 3BG, London, UK
    Eur J Pharmacol 424:53-8. 2001
    ..Moreover, the data indicate that the adrenergic system does not play a significant role in neurogenic dural vasodilation...
  38. ncbi Intravenous aspirin (lysine acetylsalicylate) in the inpatient management of headache
    M W Weatherall
    Headache Group, Department of Neurology, University of California, San Francisco, 1701 Divisadero St, San Francisco, CA 94115, USA
    Neurology 75:1098-103. 2010
    ....
  39. ncbi Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception
    T Bartsch
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
    Ann Neurol 56:371-81. 2004
    ..These findings have implications for the understanding of the action of triptans in migraine and cluster headache, suggesting that brain loci other than the trigeminal nucleus may play a role in the clinical action of triptans...
  40. ncbi Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves
    P J Goadsby
    Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    Brain Res 707:110-8. 1996
    ..It may be concluded that the parasympathetic nerves innervating the cerebral circulation contain NOS and furthermore, since blockade of NOS reduces parasympathetic vasodilatation, that NO is one of the transmitters in this system...
  41. ncbi The relationship between neuropeptide Y expression and headache in pituitary tumours
    M J Levy
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London
    Eur J Neurol 13:125-9. 2006
    ..Our data do not support a clear role for NPY pituitary tumour-associated headache...
  42. ncbi Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation
    A P Andreou
    Headache Group, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0114, USA
    Br J Pharmacol 157:464-73. 2009
    ..We investigated the possible involvement of prejunctional iGluR5 kainate receptors on CGRP release from trigeminal afferents...
  43. ncbi Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology of migraine
    A May
    Institute of Neurology, London, UK
    Brain 121:1231-7. 1998
    ..These data raise the possibility that neurogenic inflammation is not a major factor in headache attacks in migraine or cluster headache...
  44. ncbi Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Brain Res 875:119-24. 2000
    ..NMDA-mediated transmission is likely to be involved in nociceptive trigeminovascular transmission within the trigeminocervical complex and offers a possible target for both acute and preventative treatment of migraine...
  45. ncbi Stimulation of an intracranial trigeminally-innervated structure selectively increases cerebral blood flow
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Brain Res 751:247-52. 1997
    ....
  46. ncbi Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
    D Millson
    Primary Care Sciences Research Centre, Keele University, London, UK
    Cephalalgia 20:732-7. 2000
    ..This study highlights the potential to use GPRD to test targeted hypotheses exploring pharmacovigilance issues for patients using new medicines...
  47. ncbi Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects
    N J Giffin
    Headache Group, Institute of Neurology, London, UK
    Cephalalgia 23:287-92. 2003
    ..Furthermore, the adenosine A1 receptor agonist GR79236 inhibits trigeminal nociception in humans. These results support a possible therapeutic role for GR79236 in primary headache disorders...
  48. ncbi Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat
    P J Goadsby
    Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    Cephalalgia 17:153-8. 1997
    ..These receptors may, in part, be responsible for its clinical efficacy and reinforce the importance of central trigeminal neurons as a possible site of action of anti-migraine drugs...
  49. ncbi Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater
    T Bartsch
    Headache Group, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Brain 126:1801-13. 2003
    ..Understanding this interaction is likely to be pivotal in characterizing the physiology of treatment with manipulations involving cervical input, such as GON injection...
  50. ncbi TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    Acta Neurol Scand 110:137-43. 2004
    ..Taken together the findings suggest that some differences amongst triptans may be relevant in clinical practice...
  51. ncbi Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan
    P J Goadsby
    Headache Group, Institute of Neurology, London, UK
    Cephalalgia 28:383-91. 2008
    ..Treatment with almotriptan while migraine pain is still mild provides statistically significant and clinically relevant enhancements in efficacy compared with treatment when pain has reached higher severity levels...
  52. ncbi The association between calcitonin gene-related peptide (CGRP), substance P and headache in pituitary tumours
    M J Levy
    Headache Group, Institute of Neurology, Queen Square, London, UK
    Pituitary 7:67-71. 2004
    ..To determine if the differential expression of calcitonin gene-related peptide (CGRP) or substance P (SP) in a range of pituitary tumours was related to the presence or absence of headache...
  53. ncbi The role of dopamine in a model of trigeminovascular nociception
    S Akerman
    Institute of Neurology, Queen Square, London, WC1N 3BG UK
    J Pharmacol Exp Ther 314:162-9. 2005
    ..Our data do not exclude a role for dopamine receptor modulators in short- or long-term prevention...
  54. ncbi No relationship between vasoactive intestinal polypeptide expression and headache in pituitary tumours
    S Nathoo
    Headache Group, Institute of Neurology, Queen Square, London, UK
    Acta Neurol Scand 111:317-22. 2005
    ..It remains possible that the mechanism of these headaches relates to the production of either an as yet unidentified peptide, or a combination of nociceptive peptides...
  55. ncbi SUNCT syndrome secondary to prolactinoma
    M S Matharu
    Headache Group, Institute of Neurology. The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    J Neurol Neurosurg Psychiatry 74:1590-2. 2003
    ....
  56. ncbi SUNCT syndrome in the elderly
    A S Cohen
    Headache Group, Institute of Neurology, Queen Square, London, UK
    Cephalalgia 24:508-9. 2004
  57. ncbi The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study
    P J Goadsby
    Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    J Anat 190:367-75. 1997
    ..Given the close evolutionary relationship of the monkey to man it is likely that the cells described in this study represent for primates the nucleus that mediates the pain of migraine...
  58. ncbi Serotonin receptors and the acute attack of migraine
    P J Goadsby
    Institute of Neurology, Queen Square, London
    Clin Neurosci 5:18-23. 1998
    ..Future drug development will target these individual mechanisms to dissect out which, if any, determines the clinical efficacy of the compounds...
  59. ncbi Occipital activation in glyceryl trinitrate induced migraine with visual aura
    S Afridi
    Headache Group, Institute of Neurology, Queen Square, London, WC1, UK
    J Neurol Neurosurg Psychiatry 76:1158-60. 2005
    ..Activation in the primary visual area of the occipital cortex was demonstrated during the aura. This is the first published case of migraine aura triggered reproducibly by GTN...
  60. ncbi Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors
    S Akerman
    Headache Group, Institute of Neurology, Queen Square, London, WC1N 3BG, U.K
    Br J Pharmacol 142:1354-60. 2004
    ..Anandamide has been shown previously to inhibit trigeminovascular neurons and prevent vasodilation, through an action at CB(1) receptors...
  61. ncbi Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review
    R B Lipton
    Department of Neurology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Cephalalgia 24:321-32. 2004
    ....
  62. ncbi Zolmitriptan: differences from sumatriptan
    P J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Curr Med Res Opin 17:s46-50. 2001
    ..5 mg was statistically superior to sumatriptan 25 and 50 mg, although at 3.3% not clinically significant. Two comparative studies have found no difference in adverse event frequency between zolmitriptan and sumatriptan...
  63. ncbi Octreotide is not effective in the acute treatment of migraine
    M J Levy
    Headache Group, Institute of Neurology, London, UK
    Cephalalgia 25:48-55. 2005
    ..Subcutaneous octreotide 100 microg is not effective in the acute treatment of migraine when compared to placebo...
  64. ncbi Characterization of opioid receptors that modulate nociceptive neurotransmission in the trigeminocervical complex
    R J Storer
    Headache Group, Institute of Neurology, Queen Square, London WC1N 3BG
    Br J Pharmacol 138:317-24. 2003
    ..Characterizing the sub-types of opioid receptors that influence trigeminovascular nociceptive transmission is an important component to understanding the pharmacology of this synapse, which is pivotal in primary neurovascular headache...
  65. ncbi Abnormal blink reflex studies in a patient with supraorbital neuralgia
    A S Cohen
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
    Cephalalgia 26:875-8. 2006
    ..The results of the electrophysiological testing imply some central component to the pathophysiology of supra-orbital neuralgia...
  66. ncbi Increased urinary excretion of nitric oxide metabolites in longitudinally monitored migraine patients
    K Rejdak
    Department of Neuroinflammation, Institute of Neurology, London, UK
    Eur J Neurol 13:1346-51. 2006
    ..Although there is a difference in the pattern of urinary NO(x) excretion between control and migraine populations, the variable temporal association of NO(x) peaks and headaches suggests a complex role of NO in this condition...
  67. ncbi Calcitonin gene-related peptide: A molecular link between obesity and migraine?
    Ana Recober
    Headache Division Department of Neurology, University of Iowa, IA, USA
    Drug News Perspect 23:112-7. 2010
    ..Enhanced trigeminal CGRP production in obese susceptible individuals may lower the threshold necessary to trigger migraine attacks, leading to more frequent episodes and eventually to chronic migraine...
  68. ncbi New targets in the acute treatment of headache
    Peter J Goadsby
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
    Curr Opin Neurol 18:283-8. 2005
    ....
  69. ncbi Chronic daily headache
    Peter J Goadsby
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, London, UK
    J Neurol Neurosurg Psychiatry 72:ii2-ii5. 2002
  70. ncbi Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input
    Thorsten Bartsch
    Headache Group, Institute of Neurology, London, UK
    Brain 125:1496-509. 2002
    ..This mechanism may be important in pain referral from cervical structures to the head and therefore have implications for most forms of primary headache...
  71. ncbi Effectiveness of intranasal zolmitriptan in acute cluster headache: a randomized, placebo-controlled, double-blind crossover study
    Elizabeth Cittadini
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, England
    Arch Neurol 63:1537-42. 2006
    ..Trial Registration controlled-trials.com Identifier ISCRTN27362692...
  72. ncbi Post-triptan era for the treatment of acute migraine
    Peter J Goadsby
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Curr Pain Headache Rep 8:393-8. 2004
    ..Development of one or more such compound offers the exciting prospect of new non-vasoconstrictor treatments for migraine and cluster headache...
  73. ncbi Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?
    Kevin G Shields
    Headache Group, Institute of Neurology, London, UK
    Neurobiol Dis 23:491-501. 2006
    ....
  74. ncbi Chronic daily headache: nosology and pathophysiology
    K Michael A Welch
    University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Curr Opin Neurol 15:287-95. 2002
    ....
  75. ncbi Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons
    Simon Akerman
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom
    J Pharmacol Exp Ther 320:64-71. 2007
    ....
  76. ncbi Acromegaly
    Peter J Goadsby
    N Engl J Med 356:1274; author reply 1275-6. 2007
  77. ncbi Recent advances in understanding migraine mechanisms, molecules and therapeutics
    Peter J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Trends Mol Med 13:39-44. 2007
    ..These data lead to the view that migraine is a form of sensory dysmodulatio--a system failure of normal sensory processing...
  78. ncbi Headache
    Peter J Goadsby
    Curr Opin Neurol 15:285-6. 2002
  79. ncbi Trigeminal autonomic cephalalgias: diagnosis and treatment
    Peter J Goadsby
    Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Curr Neurol Neurosci Rep 7:117-25. 2007
    ..The management of TACs can be very rewarding for physicians and highly beneficial to patients...
  80. ncbi Trigeminal autonomic cephalalgias: current and future treatments
    Anna S Cohen
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Headache 47:969-80. 2007
    ..The involvement of the hypothalamus in functional imaging studies implies that this may be a substrate for targeting treatment options in the future...
  81. ncbi Migraine--current understanding and treatment
    Peter J Goadsby
    Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK
    N Engl J Med 346:257-70. 2002
  82. ncbi Cluster headache: a prospective clinical study with diagnostic implications
    Anish Bahra
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, United Kingdom
    Neurology 58:354-61. 2002
  83. ncbi Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society
    Elliott A Schulman
    Lankenau Hospital, Wynnewood, PA, USA
    Headache 48:778-82. 2008
    ..The definition also employs modifiers for the presence or absence of medication overuse, and with or without significant disability...
  84. ncbi Persistence of attacks of cluster headache after trigeminal nerve root section
    Manjit S Matharu
    Headache Group, Institute of Neurology, University College London, UK
    Brain 125:976-84. 2002
    ..The case illustrates that cluster headache may be generated primarily from within the brain, and that triptans may have anti-headache effects through an entirely central mechanism...
  85. ncbi Is medication-overuse headache a distinct biological entity?
    Peter J Goadsby
    Nat Clin Pract Neurol 2:401. 2006
  86. ncbi Understanding migraine in women
    Manjit S Matharu
    Headache Group, Institute of Neurology, National Hospital for Neurology and Neurosurgery, London
    Practitioner 246:272-8. 2002
  87. ncbi Occipital nerve stimulation for headache: mechanisms and efficacy
    Peter J Goadsby
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Headache 48:313-8. 2008
    ..Other device-based therapies, such as deep brain stimulation for cluster headache and patent foramen ovale closure, are covered elsewhere...
  88. ncbi Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database
    David W Dodick
    Department of Neurology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Headache 48:184-93. 2008
    ....
  89. ncbi Neurostimulation in primary headache syndromes
    Peter J Goadsby
    Headache Group, Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Expert Rev Neurother 7:1785-9. 2007
    ..The initial results are encouraging and given the very significant disability of medically intractable primary headaches, this is a very promising area for patients and physicians alike...
  90. ncbi Emerging therapies for migraine
    Peter J Goadsby
    Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Nat Clin Pract Neurol 3:610-9. 2007
    ..There is much cause for optimism in this area of neurology and considerable benefit awaits our patients...
  91. ncbi Dopamine inhibits trigeminovascular transmission in the rat
    Astrid Bergerot
    Headache Group, Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, United Kingdom
    Ann Neurol 61:251-62. 2007
    ..Clinical evidence, such as premonitory or postdromal symptoms, indicate involvement of dopamine in the pathophysiology of migraine...
  92. ncbi Headache: a good year for research
    Peter J Goadsby
    Headache Group, Institute of Neurology, University College, Queen Square, London, UK
    Lancet Neurol 5:5-6. 2006
  93. ncbi Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?
    Kevin G Shields
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK
    Brain 128:86-97. 2005
    ..Thalamic involvement in migraine is attractive given the complex and widespread nature of the sensory disturbance...
  94. ncbi Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project)
    F Michael Cutrer
    Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Ther 26:1533-45. 2004
    ..Physicians treating patients with migraine can now choose from among 7 triptans, which differ on a range of attributes that may be important for treatment selection...
  95. ncbi Does chronic daily headache arise de novo in association with regular use of analgesics?
    Anish Bahra
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK
    Headache 43:179-90. 2003
    ....
  96. ncbi Therapeutic gain or therapeutic ratio?
    Peter J Goadsby
    Headache 43:814-5; author reply 815-6. 2003
  97. ncbi GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil
    Robin James Storer
    Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK
    Brain Res 1013:188-93. 2004
    ..These data are consistent with the useful clinical effects reported with compounds that can augment GABAergic transmission in the central nervous system (CNS)...
  98. ncbi Neurogenic vasodilation of dural blood vessels is not mediated by cholinergic transmission in the anaesthetised rat
    Fernando Kowacs
    Headache Group, Institute of Neurology, Queen Square, London WC1N 3BG, UK
    Eur J Pharmacol 493:133-7. 2004
    ..538). Cholinergic dilation of the rat dural arteries is mediated by muscarinic receptors, but this mechanism does not play a significant role in the rat dural vessel dilation induced by closed cranial window electrical stimulation...
  99. ncbi The future of headache
    Peter J Goadsby
    Headache Group, Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 251:630-6. 2004
  100. ncbi A meta-analysis for headache in systemic lupus erythematosus: the evidence and the myth
    Dimos D Mitsikostas
    Athens Naval Hospital, Department of Neurology, Headache Clinic, Athens, Greece
    Brain 127:1200-9. 2004
    ..These recommendations should be verified by a properly controlled and prospective study in both adult and paediatric populations...
  101. ncbi Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
    Jes Olesen
    Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark
    N Engl J Med 350:1104-10. 2004
    ..Calcitonin gene-related peptide (CGRP) may have a causative role in migraine. We therefore hypothesized that a CGRP-receptor antagonist might be effective in the treatment of migraine attacks...